NCT01026662Unknown不适用
In-vivo Analysis of a Fractional CO2 Laser System (eMatrixCO2) Intended for Treatment of Soft Tissue
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Record number and type of any AE during the study
研究概览
简要总结
This study will:
Evaluate the in vivo effects of treatment with eMatrixCO2 and to determine the dynamics of their development over time following treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed consent agreement signed by the subject.
- •Healthy males or females older than 21 to 60 years of age.
- •Fitzpatrick skin type I-V (Although the systems are cleared for all skin types I-VI, it is recommended to use the Matrix applicators on skin types I - V).
- •Willingness to follow the treatment and follow-up schedule and the post-treatment care.
- •For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).
排除标准
- •Pregnant and/or breastfeeding.
- •Having a history of diseases stimulated by heat, such as recurrent Herpes
- •Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
- •Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session.
- •Use of retinoids, antioxidants or therapeutic skin nourishing supplements at medicinal concentration within 2 months of treatment or during the study and oral retinoids within 6 months of the study.
- •Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study.
- •Having received collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study.
- •Having received Botox in the treated area within 6 months of treatment or during the study.
- •Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study.
- •History of keloid scarring or of abnormal wound healing.
- •Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
- •History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
- •History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
- •History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
- •Suffering from hormonal imbalance, as per the Investigator's discretion.
- •Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
- •Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions.
- •Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders.
- •Vascular lesion, tattoo or permanent make-up in the treated area.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •Participation in a study of another device or drug within three month prior to enrollment or during the study.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
结局指标
主要结局
Record number and type of any AE during the study
时间窗: Throughout study
Histological and molecular assessment of tissue taken following treatment with different parameters and at various time points
时间窗: Immediate, 1, 3, 10, 30 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The effects of Laser and Microneedling combined with phototherapy for treating vitiligo in resistant of hair skiIRCT2017032530808N3Vice chancellor for research, Jahrom University of Medical Sciences20
已完成
4 期
Fractional Laser Assisted Delivery of AnestheticsLocal Anesthesia of the Skin.NCT02246179Netherlands Institute for Pigment Disorders10
撤回
不适用
MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN StudyBreast Cancer FemaleGenitourinary Syndrome of MenopauseNCT04606550Mount Sinai Hospital, Canada
Unknown
不适用
Carbon Dioxide（CO2）Fractional Laser Plus Photodynamic Therapy in Female Patients With Vulvar Lichen SclerosusVulva Lichen SclerosusNCT05228483Xijing Hospital134
尚未招募
2 期
se of fractional CO2 laser for the treatment of various scarsCTRI/2023/10/058683Mahatma Gandhi Medical Colege and Hospital